Harvard Medical School and Massachusetts General Hospital have expanded their Meditation Research Program to study 'meditative endpoints'—advanced states of awareness achieved after extensive practice ...
13 分钟
Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back ...
FDA has previously agreed on the design of this 300-patient randomized, placebo-controlled confirmatory Phase 3 trial, and the 12-month primary endpoint of pain reduction as an approvable indication.
Jyong Biotech Ltd. (Nasdaq: MENS) (the Company or Jyong Biotech), a science-driven biotechnology company dedicated to the ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果